Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Bell Tolls For Fedratinib In A Setback For Sanofi’s Oncology Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has halted clinical trials testing its Phase III JAK2 inhibitor fedratinib after determining that the risks of treatment outweigh the benefit after cases of the neurological condition Wernicke’s encephalopathy emerged in patients.

You may also be interested in...



Sanofi Oncology Strategy: A New Lease On Cancer R&D

The company is rebooting after several late-stage setbacks in cancer R&D, relying on a collaboration with Regeneron to vault it into the field of immuno-oncology.

On The Offense: Sanofi Suits Up For A Game Change

Having exited its patent cliff and advanced several drugs into late-stage development, Sanofi is moving into a new commercial-centric phase. Its future looks bright, but success is not guaranteed.

Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term

The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel